- |||||||||| Journal: Pituitary lactotroph adenomas resistant to dopamine agonist treatment: histological and immunohistochemical characteristics (Pubmed Central) - Apr 30, 2019
These data point to a unique disturbance of the cAMP-PDE pathway in AIP-mutation positive adenomas, which may help to explain their well-described poor response to somatostatin analogue. PLAs resistant to dopamine agonists in addition to PRL (100%) can express GH in 16% of cases are characterized by the immunoexpression of DR (42%) and ERĪ± (32%), a low proliferative activity, increased angiogenesis in the adenomas with parasellar growth and invasion into the cavernous sinus.
- |||||||||| Foscavir (foscarnet) / Pfizer, Clinigen
Journal: Nonparathyroid Hypercalcemia. (Pubmed Central) - Apr 28, 2019
Vitamin D intoxication may cause hypercalcemia due to overproduction of the metabolite, 25 hydroxyvitamin D, apparently in the absence of conversion to 1,25(OH)2D. Malignancies metastatic to bone or arising in bone (such as multiple myeloma) may produce a variety of growth factors and cytokines, in addition to PTHrP, which can contribute to tumor growth as well as osteolysis and hypercalcemia.
- |||||||||| Clinical, Journal: Primary versus postoperative stereotactic radiosurgery for acromegaly: a multicenter matched cohort study. (Pubmed Central) - Apr 27, 2019
There were no differences in the rates of radiological tumor control (p = 0.34), initial endocrine remission (p = 0.23), biochemical recurrence after initial remission (p = 0.33), recurrence-free survival (p = 0.32), or hypopituitarism (p = 0.67) between the 2 matched cohorts.CONCLUSIONSPrimary SRS has a reasonable benefit-to-risk profile for patients with acromegaly in whom resection is not possible, and it has similar outcomes to endocrinologically comparable patients who undergo postoperative SRS. SRS with medical therapy in the latent period can be used as an alternative to surgery in selected patients who cannot or do not wish to undergo resection.
- |||||||||| Journal: NECESSITY OF MULTIMODAL TREATMENT OF ACROMEGALY AND OUTCOMES. (Pubmed Central) - Apr 26, 2019
In patients with persistent acromegaly following surgery, multiple treatment modalities, including RT, may be required to achieve remission. Treatment outcome uncertainty and the need for multiple interventions add to the disease burden associated with persistent acromegaly.
- |||||||||| Journal: Pituitary Disease in Pregnancy: Special Aspects of Diagnosis and Treatment? (Pubmed Central) - Apr 20, 2019
If one of the partners has a pituitary disorder, it is often still possible for many couples to achieve their wish of having children if they receive medical support to plan and the pregnancy is carefully monitored. Given the complexity of pituitary disease, pregnant patients with pituitary disorders should be cared for and treated by a multidisciplinary team in centers specializing in the diagnosis and treatment of pituitary disease.
- |||||||||| Trial initiation date: Modulating the GIP System in Patients With Acromegaly Due to a Pituitary Tumor (clinicaltrials.gov) - Apr 17, 2019
P=N/A, N=30, Not yet recruiting,
These results provide insight into the relative tumor biology and disease course after radiosurgery that will serve to further improve clinical outcomes and patient treatment in the future. Initiation date: Feb 2019 --> Jun 2019
- |||||||||| Somavert (pegvisomant) / Pfizer, Signifor LAR (pasireotide) / Novartis
Clinical, Journal: Efficacy and safety of long-acting pasireotide in pateints with somatostatin-resistant acromegaly: a multicenter study. (Pubmed Central) - Apr 11, 2019
Reduction of serum GH after surgical treatment of acromegaly was associated with dynamic increases of IHL, abdominal visceral, and subcutaneous fat, but a reduction of facial subcutaneous fat. In the real-life scenario ~54% of patients with acromegaly resistant to first-generation SSA, may normalize IGF-1 with pasireotide; however, 63% experienced glucose control deterioration.
- |||||||||| Journal: Temporal relationship of sleep apnea and acromegaly: a nationwide study. (Pubmed Central) - Apr 11, 2019
Sleep apnea is common among patients with acromegaly, and is often diagnosed prior to their acromegaly diagnosis. These results support early screening for sleep apnea in patients with acromegaly and awareness for acromegaly in patients with sleep apnea.
- |||||||||| Journal: Treatment of pituitary adenomas (Pubmed Central) - Apr 10, 2019
The primary therapy for prolactinomas is pharmacological treatment with dopamine agonists. Multidisciplinary collaboration among endocrinologists, neurosurgeons and radiosurgeons is necessary in the treatment of pituitary adenomas.
- |||||||||| Biomarker, Preclinical, Journal: Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages. (Pubmed Central) - Apr 7, 2019
Invasive growth and aggressive histological subtypes predicted disease persistence/recurrence. This series also highlights the importance of routine application of pituitary cell lineage transcription factors along with hormones to distinguish and subtype multiple synchronous PitNETs.
- |||||||||| Retrospective data, Journal: Radiographic Predictors of Difficult Laryngoscopy in Acromegaly Patients. (Pubmed Central) - Apr 5, 2019
Old age and radiographic predictors indicating large tongue size (large TA, long alveolar line of the mandible to the hyoid bone and mandible to the hyoid bone) were associated with an increased rate of difficult laryngoscopy in acromegaly patients. Preoperative radiographic measurements of tongue size can be helpful for safe airway management in such patients.
- |||||||||| Journal: A designed cell-penetrating human SOCS2 protein suppresses GH-dependent cancer cell proliferation. (Pubmed Central) - Apr 5, 2019
Our results suggest that the designed cell-penetrating SOCS2 protein will be useful in intercellular protein therapy to cure cancers. Abbreviations: SOCS: suppressor of cytokine signaling; GH: growth hormone; GHR: growth hormone receptor; IGF-1: insulin-like growth factor 1; CP: cell-penetrating; STAT: signal transducer and activator of transcription; JAK: Janus kinase; HNF: hepatocyte nuclear factor; MTM: membrane-translocating motif; HIV: human immunodeficiency virus.
- |||||||||| Review, Journal: Phosphodiesterases and cAMP Pathway in Pituitary Diseases. (Pubmed Central) - Apr 4, 2019
Based on the association of low PDE4A4 expression with germline AIP-mutation-positive samples, the available data suggest that lack of AIP hinders the upregulation of PDE4A4 protein seen in sporadic somatotrophinomas. This unique disturbance of the cAMP-PDE pathway observed in the majority of AIP-mutation positive adenomas could contribute to their well-described poor response to somatostatin analogs and may support a role in tumorigenesis.
- |||||||||| Somavert (pegvisomant) / Pfizer
Review, Journal: Bringing Cardiovascular Comorbidities in Acromegaly to an Update. How Should We Diagnose and Manage Them? (Pubmed Central) - Apr 2, 2019
In many cases, this approach may be performed using straightforward screening tools, which will guide us for further diagnosis and management of cardiovascular complications. This article focuses on those cardiovascular comorbidities that are most frequently encountered in acromegalic patients, describes their pathophysiology, and suggests some recommendations for an early and optimal diagnosis, management and treatment.
- |||||||||| Trial completion date, Trial primary completion date: MAC: Muscle in Acromegaly and Cushing's Syndrome (clinicaltrials.gov) - Feb 25, 2019
P=N/A, N=120, Recruiting,
Robotic SRS is a safe and effective treatment for acromegaly: radiation-induced visual complications and hypopituitarism is rare. Trial completion date: Jan 2019 --> Jan 2020 | Trial primary completion date: Oct 2018 --> Oct 2019
- |||||||||| Trial completion date, Trial primary completion date: Treatment Patterns and Treatment Outcomes for Acromegaly (clinicaltrials.gov) - Feb 19, 2019
P=N/A, N=520, Recruiting,
Trial completion date: Jan 2019 --> Jan 2020 | Trial primary completion date: Oct 2018 --> Oct 2019 Trial completion date: Jul 2019 --> Jul 2020 | Trial primary completion date: Jul 2018 --> Jul 2019
- |||||||||| Somavert (pegvisomant) / Pfizer
Trial completion date, Trial primary completion date: Bone MicroArchitecture in Acromegaly (clinicaltrials.gov) - Feb 19, 2019
P=N/A, N=25, Recruiting,
Trial completion date: Jul 2019 --> Jul 2020 | Trial primary completion date: Jul 2018 --> Jul 2019 Trial completion date: Dec 2018 --> Mar 2020 | Trial primary completion date: Dec 2018 --> Mar 2020
- |||||||||| Somavert (pegvisomant) / Pfizer
Trial completion date, Trial primary completion date: Acromegaly Combination Treatment Study (clinicaltrials.gov) - Jan 31, 2019
P=N/A, N=51, Recruiting,
Recruiting --> Completed | Phase classification: P4 --> PN/A Trial completion date: Dec 2019 --> Mar 2020 | Trial primary completion date: Dec 2018 --> Mar 2020
- |||||||||| NN1213 / Novo Nordisk
Enrollment open, Trial completion date, Trial primary completion date, Patient reported outcomes: MPOWERED: Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly (clinicaltrials.gov) - Dec 12, 2018
P3, N=150, Recruiting,
Trial completion date: Jan 2019 --> Apr 2019 | Trial primary completion date: Jan 2019 --> Apr 2019 Active, not recruiting --> Recruiting | Trial completion date: Mar 2019 --> Feb 2021 | Trial primary completion date: Oct 2018 --> Aug 2020
- |||||||||| NN1213 / Novo Nordisk
Trial completion: Validation Study of the SAGIT (clinicaltrials.gov) - Nov 1, 2018
P=N/A, N=227, Completed,
Active, not recruiting --> Completed Active, not recruiting --> Completed
|
